Personalis, Inc. Common Stock (PSNL) — Analysis Summary
Personalis, Inc. Common Stock (PSNL) has a market cap of $1.58B with year-over-year revenue growth of -17.7%. Net margin stands at -116.7%. The stock trades at a P/E ratio of -16.5.
Key Takeaways
- Revenue changed -17.7% year-over-year
- Net margin of -116.7%
- P/E ratio of -16.5
Compared to other companies in the SERVICES-MEDICAL LABORATORIES sector, PSNL posted revenue growth of -17.7% and trades at a P/E of -16.5.
Personalis, Inc. Common Stock (PSNL)
UPDATED — ET · SOURCE POLYGON
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Interest coverage at -457.7x — earnings do not cover interest payments
Operating margin at -158.9% — severe operating losses
Net margin at -148.1% — losses exceed revenue (possible one-time charges)
The latest filing shows negative free cash flow.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. The company' products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
Sector
SERVICES-MEDICAL LABORATORIES
Employees
260
Headquarters
FREMONT, CA
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.